<DOC>
	<DOC>NCT01153724</DOC>
	<brief_summary>This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol</brief_summary>
	<brief_title>Relative Bioavailability of Olodaterol and Fluconazole</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Inclusion criteria: Healthy male and female volunteers</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>